NCT02338856View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Metabolic Syndrome
Interventions
DRUG

MB12066 200mg

100mg bid (multiple dose, day 8)

DRUG

Placebo

100mg bid (multiple dose, day 8)

Trial Locations (1)

700-721

Kyungpook National University Hospital, Daegu

All Listed Sponsors
lead

Yungjin Pharm. Co., Ltd.

INDUSTRY

NCT02338856 - Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter